Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer
Introduction: Despite improvements in radiation therapy, chemotherapy and surgical procedures over the last 30 years, pancreatic cancer 5-year survival rate remains at 9%. Reduced stroma permeability and heterogeneous blood supply to the tumour prevent chemoradiation from making a meaningful impact...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/1/163 |
| _version_ | 1797765232343384064 |
|---|---|
| author | Mikaela Dell’Oro Michala Short Puthenparampil Wilson Eva Bezak |
| author_facet | Mikaela Dell’Oro Michala Short Puthenparampil Wilson Eva Bezak |
| author_sort | Mikaela Dell’Oro |
| collection | DOAJ |
| description | Introduction: Despite improvements in radiation therapy, chemotherapy and surgical procedures over the last 30 years, pancreatic cancer 5-year survival rate remains at 9%. Reduced stroma permeability and heterogeneous blood supply to the tumour prevent chemoradiation from making a meaningful impact on overall survival. Hypoxia-activated prodrugs are the latest strategy to reintroduce oxygenation to radioresistant cells harbouring in pancreatic cancer. This paper reviews the current status of photon and particle radiation therapy for pancreatic cancer in combination with systemic therapies and hypoxia activators. Methods: The current effectiveness of management of pancreatic cancer was systematically evaluated from MEDLINE<sup>®</sup> database search in April 2019. Results: Limited published data suggest pancreatic cancer patients undergoing carbon ion therapy and proton therapy achieve a comparable median survival time (25.1 months and 25.6 months, respectively) and 1-year overall survival rate (84% and 77.8%). Inconsistencies in methodology, recording parameters and protocols have prevented the safety and technical aspects of particle therapy to be fully defined yet. Conclusion: There is an increasing requirement to tackle unmet clinical demands of pancreatic cancer, particularly the lack of synergistic therapies in the advancing space of radiation oncology. |
| first_indexed | 2024-03-12T20:07:28Z |
| format | Article |
| id | doaj.art-da9f4df03b6a434c9239356479b4f161 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T20:07:28Z |
| publishDate | 2020-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-da9f4df03b6a434c9239356479b4f1612023-08-02T01:59:48ZengMDPI AGCancers2072-66942020-01-0112116310.3390/cancers12010163cancers12010163Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic CancerMikaela Dell’Oro0Michala Short1Puthenparampil Wilson2Eva Bezak3Cancer Research Institute and School of Health Sciences, University of South Australia, Adelaide SA 5001, AustraliaCancer Research Institute and School of Health Sciences, University of South Australia, Adelaide SA 5001, AustraliaDepartment of Radiation Oncology, Royal Adelaide Hospital, Adelaide SA 5000, AustraliaCancer Research Institute and School of Health Sciences, University of South Australia, Adelaide SA 5001, AustraliaIntroduction: Despite improvements in radiation therapy, chemotherapy and surgical procedures over the last 30 years, pancreatic cancer 5-year survival rate remains at 9%. Reduced stroma permeability and heterogeneous blood supply to the tumour prevent chemoradiation from making a meaningful impact on overall survival. Hypoxia-activated prodrugs are the latest strategy to reintroduce oxygenation to radioresistant cells harbouring in pancreatic cancer. This paper reviews the current status of photon and particle radiation therapy for pancreatic cancer in combination with systemic therapies and hypoxia activators. Methods: The current effectiveness of management of pancreatic cancer was systematically evaluated from MEDLINE<sup>®</sup> database search in April 2019. Results: Limited published data suggest pancreatic cancer patients undergoing carbon ion therapy and proton therapy achieve a comparable median survival time (25.1 months and 25.6 months, respectively) and 1-year overall survival rate (84% and 77.8%). Inconsistencies in methodology, recording parameters and protocols have prevented the safety and technical aspects of particle therapy to be fully defined yet. Conclusion: There is an increasing requirement to tackle unmet clinical demands of pancreatic cancer, particularly the lack of synergistic therapies in the advancing space of radiation oncology.https://www.mdpi.com/2072-6694/12/1/163pancreatic cancerproton therapycarbon ion therapystereotactic body radiation therapyhypoxia activated prodrugradiosensitizer |
| spellingShingle | Mikaela Dell’Oro Michala Short Puthenparampil Wilson Eva Bezak Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer Cancers pancreatic cancer proton therapy carbon ion therapy stereotactic body radiation therapy hypoxia activated prodrug radiosensitizer |
| title | Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer |
| title_full | Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer |
| title_fullStr | Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer |
| title_full_unstemmed | Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer |
| title_short | Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer |
| title_sort | clinical limitations of photon proton and carbon ion therapy for pancreatic cancer |
| topic | pancreatic cancer proton therapy carbon ion therapy stereotactic body radiation therapy hypoxia activated prodrug radiosensitizer |
| url | https://www.mdpi.com/2072-6694/12/1/163 |
| work_keys_str_mv | AT mikaeladelloro clinicallimitationsofphotonprotonandcarboniontherapyforpancreaticcancer AT michalashort clinicallimitationsofphotonprotonandcarboniontherapyforpancreaticcancer AT puthenparampilwilson clinicallimitationsofphotonprotonandcarboniontherapyforpancreaticcancer AT evabezak clinicallimitationsofphotonprotonandcarboniontherapyforpancreaticcancer |